Yeni tanılı ve klinik takip altındaki metabolik sendromlu hastalarda serum ferritin düzeylerinin karşılaştırılması

Abstract

Amaç: Bu çalışmada yeni tanılı ve klinik takip altındaki metabolik sendromlu hastalarda serum ferritin düzeylerinin karşılaştırılmasını amaçladık. Materyal ve metod: NCEP ATP III kriterlerine göre yeni metabolik sendrom tanısı konan 51 hasta ile konvansiyonel insülin direnci tedavisi alan metabolik sendrom tanılı 179 hastada serum ferritin düzeyleri karşılaştırıldı.Bulgular: Serum ferritin ve HOMA-IR düzeyleri yeni metabolik sendrom tanısı alanlarda, tedavi alan diğer metabolik sendromlu hastalara göre anlamlı yüksek tespit edildi her ikisi için p

Keywords

• Ferritin,metabolik sendrom,insülin direnci

Comparison of serum ferritin levels between newly diagnosed and clinical follow-up patients with metabolic syndrome

Abstract

Background: The purpose of this study was to compare serum ferritin levels between newly diagnosed and clinical follow-up patients with metabolic syndrome. Methods: Fifty-one newly diagnosed patients with metabolic syndrome according to the NCEP ATP III criteria were compared 179 patients with metabolic syndrome who have receiving conventional insulin resistance therapy. Results: Ferritin and HOMA-IR levels in newly diagnosed patients with metabolic syndrome were significantly higher than clinical follow-up patients with metabolic syndrome both p

Keywords

• Ferritin,metabolic syndrome,insulin resistance

References

1. ) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–97.
2. ) Reaven G. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation 2002; 106: 286–8.
3. ) Isomaa B. A major health hazard: the metabolic syndrome. Life Sci 2003; 73: 2395–411.
4. ) Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all cause in United States adults. Circulation 2004; 110: 1245–50.
5. ) Fernandez-Real JM, Lopez-Bermejo A, Ricart W. Cross-talk between iron metabolism and diabetes. Diabetes 2002; 51: 2348–54.
6. ) Jehn M, Clark JM, Guallar E. Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care 2004; 27: 2422-8.
7. ) Salonen JT, Tuomainen TP, Nyyssonen K, Lakka HM, Punnonen K. Relation between iron stores and non-insulin dependent diabetes in men: case-control study. BMJ 1998; 317: 727.
8. ) Jiang R, Manson JE, Meigs JB, Ma J, Rifai N, Hu FB. Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA 2004; 291: 711–7.

9. ) Tuomainen TP, Nyyssonen K, Salonen R, et al. Body iron stores are associated with serum insulin and blood glucose concentrations: population study in 1,013 eastern Finnish men. Diabetes Care 1997; 20: 426–8.
10. ) Fernandez-Real JM, Ricart-Engel W, Arroyo E, et al. Serum ferritin as a component of the insulin resistance syndrome. Diabetes Care 1998; 21: 62–8.
11. ) Sheu WH, Chen YT, Lee WJ, Wang CW, Lin LY. A relationship between serum ferritin and the insulin resistance syndrome is present in non-diabetic women but not in non-diabetic men. Clin Endocrinol 2003; 58: 380–5.
12. ) Festa A, D'Agostino R, Tracey RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor- 1 predict the development of type 2 diabetes. Diabetes 2002; 51: 1131–7.
13. ) Piperno A, Trombini P, Gelosa M, et al. Increased serum ferritin is common in men with essential hypertension. J Hypertens 2002; 20: 1513–8.
14. ) Williams MJ, Poulton R, Williams S. Relationship of serum ferritin with cardiovascular risk factors and inflammation in young men and women. Atherosclerosis 2002; 165: 179–184.
15. ) Bonora E, Kiechl S, Willeit J, et al. Carotid atherosclerosis and coronary heart disease in the metabolic syndrome; prospective data from the Bruneck study. Diabetes Care 2003; 26: 1251–7.
16. ) Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003; 52: 1210–4.
17. ) Halle M, Konig D, Berg A, Keul J, Baumstark MW. Relationship of serum ferritin concentrations with metabolic cardiovascular risk factors in men without evidence for coronary artery disease. Atherosclerosis 1997; 128: 235–40.
18. ) Gillum RF. Association of serum ferritin and indices of body fat distribution and obesity in Mexican American men: the Third National Health and Nutrition Examination Survey. Int J Obes Relat Metab Disord 2001; 25: 639–45.
19. ) Ferrannini E. Insulin resistance, iron, and the liver. Lancet 2000; 355: 2181–2.
20. ) Niederau C, Berger M, Stremmel W, et al. Hyperinsulinaemia in non-cirrhotic haemochromatosis: impaired hepatic insulin degradation? Diabetologia 1984; 26: 441–4.
21. ) Ford ES, Cogswell ME. Diabetes and serum ferritin concentration among U.S. adults. Diabetes Care 1999; 22: 1978–83.
22. ) Wolff SP. Diabetes mellitus and free radicals: free radicals, transition metals and oxidative stress in the aetiology of diabetes mellitus and complications. Br Med Bull 1993; 49: 642–52.
23. ) Wilson JG, Lindquist JH, Grambow SC, Crook ED, Maher JF. Potential role of increased iron stores in diabetes. Am J Med Sci 2003; 325: 332–9.
24. ) Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448–54.
25. ) Witte DL, Crosby WH, Edwards CQ, Fairbanks VF, Mitros FA. Practice guideline development task force of the College of American Pathologists: hereditary hemochromatosis. Clin Chim Acta 1996; 245: 139–200.
26. ) Fumeron F, Pean F, Driss F, et al. DESIR Study Group: Ferritin and transferrin are both predictive of the onset of hyperglycemia in men and women over 3 years: the Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR) study. Diabetes Care 2006; 29: 2090–4.
27. ) Iwasaki T, Nakajima A, Yoneda M, et al. Serum ferritin is associated with visceral fat area and subcutaneous fat area. Diabetes Care 2005; 28: 2486-91.
28. ) Kiechl S, Willeit J, Egger G, Poewe W, Oberhollenzer F. Body iron stores and the risk of carotid atherosclerosis:prospective results from the Bruneck study. Circulation 1997; 96: 3300-7.
29. ) Van der A DL, Grobbee DE, Roest M, Marx JJ, Voorbij HA, Van der Schouw YT. Serum ferritin is a risk factor for stroke in postmenopausal women. Stroke 2005; 36: 1637-41.